- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about SciSparc
Recent news which mentions SciSparc
From Benzinga
SciSparc, Deere & Company, Baidu, Marathon Digital, Tesla: Why These 5 Stocks Are On Investors' Radars Today
November 22, 2023
From Benzinga
SciSparc Signs LOI to Sell 50% Interest in Subsidiary
December 15, 2022
From Benzinga
Can This Company's Positive Results For Psychedelic Combination Treatment Provide Hope For Alcohol And Cocaine Addiction Problems?
November 15, 2022
Tickers
AMPH
From Benzinga
SciSparc Nutraceuticals Signs Agreement With Logistics Facilities, Expected To Optimize Handling and Shipment Processes and Reduce Direct Sales Costs
November 02, 2022
Tickers
SPRC
From Benzinga
SciSparc Enters Agreement to Acquire Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million
September 14, 2022
Tickers
SPRC
From Benzinga
Additional Positive Results Revealed In Cocaine Addiction Treatment Through SciSparc-Clearmind Collaboration
August 25, 2022
From Benzinga
From Benzinga
Psychedelic-Based Cocaine Addiction Treatment Study Showing Positive Results. This Is What We Know
August 24, 2022
From Benzinga
SciSparc Issued Israeli Patent For Its Core Technology For Treating Central Nervous Systems Disorders
August 12, 2022
Tickers
SPRC
From Benzinga
From Benzinga
SciSparc Completes Development Of Its Proprietary Drug Candidate SCI-110 To Treat Tourette Syndrome
June 30, 2022
Tickers
SPRC
From Benzinga
SciSparc And Polyrizon Report Joining Forces To Develop A Non-Opioid Pain Relief Nasal Spray
June 28, 2022
From Benzinga
SciSparc Receives Ethics Committee Approval To Conduct Clinical Trial In ASD With Proprietary SCI-210 Treatment
June 24, 2022
Tickers
SPRC
From Benzinga
SciSparc Announces Ethics Committee Approval To Conduct Its Clinical Trial In Autism Spectrum Disorder
June 23, 2022
Tickers
SPRC
From Benzinga
SciSparc Reinforces Its New JV For Targeting Discovery With A Global Expert In The Field Of Mitochondrial Transport Proteins
June 15, 2022
Tickers
SPRC
From Benzinga
SciSparc Ltd. Announces Initial Positive Results For The Cocaine Addiction Treatment Of Clearmind Medicine Inc.
June 07, 2022
From Benzinga
From Benzinga
SciSparc To Collaborate With Polyrizon For Brain Targeting Using Intranasal Hydrogel Systems
May 31, 2022
Tickers
SPRC
From Benzinga
SciSparc Gets Ethics Committee Approval In Germany And Israel Sites To Conduct A Phase IIb Trial In Tourette Syndrome
May 27, 2022
Tickers
SPRC
From Benzinga
SciSparc Announces Ethics Committee Approval to Conduct a Phase IIb Trial In Tourette Syndrome
May 26, 2022
Tickers
SPRC
From Benzinga
From Benzinga
SciSparc And Clearmind Medicine Inc. Collaboration Yields Positive Results For Its Psychedelic Combination Treatment
May 24, 2022
Tickers
SPRC
From Benzinga
SciSparc Reports Developing Cannabinoids Based Acute Pain Relief Alternative To Help Counter Opioid Crisis
May 18, 2022
From Benzinga
SciSparc Reports Developing Cannabinoids Based Acute Pain Relief Alternative To Help Counter Opioid Crisis
May 18, 2022
From Benzinga
SciSparc Issued Israeli Patent For Its Core Technology For Treating Central Nervous Systems Disorders
May 17, 2022
Tickers
SPRC
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.